Mindstate Design Labs

MSD-001 Phase 1 delivers a clean safety profile and compelling pharmacodynamic biomarkers by late 2026, enabling a Series B at ~$200-250M post-money (~3-4x the estimated current post-money of ~$60M); a major pharma licensing deal further inflates paper equity 3-4x from grant price, though the $24.3M preference stack must be cleared before common holders participate in any exit proceeds.

Phase 1 completes on schedule but with unremarkable efficacy signals, requiring a bridge or Series B at a modest premium that dilutes common holders 20-30%; with no revenue, no near-term liquidity event, and a psychedelic biotech sector that remains niche and illiquid, paper equity is flat-to-negative on a 2-year mark. The 7-person team has not yet scaled operations to support a multi-asset pipeline.

A safety signal or null efficacy result in Phase 1 collapses the investment thesis; with $24.3M already deployed into a pre-revenue asset and very high capital intensity requiring $50M+ more to reach Phase 2, a down round or wind-down wipes out most common equity value. Psychedelic biotech funding sentiment deteriorates and secondary bids on a 7-person company are negligible.